37 citations,
May 2003 in “Journal of Consumer Marketing”
The debate on direct-to-consumer pharmaceutical ads continues, with consumers finding them educational and doctors concerned about their impact on patient relationships and medication understanding.
The conversation discusses using 1% cetirizine, an antihistamine, as a potential treatment for androgenetic alopecia (hair loss). One user plans to try cetirizine instead of finasteride, while others are curious or skeptical about its effectiveness, discussing the role of inflammation in hair loss.
A user experienced an allergic reaction, including swollen lymph nodes, to Minoxidil 5% with an aqueous base. Switching to a non-alcohol-based Minoxidil (Prolox 5%) resolved the allergies.
The user has been taking finasteride for a year without improvement and added minoxidil and dermarolling recently, but hair loss continues. Blood tests showed normal testosterone and vitamins, except for low vitamin D3 and an allergy, which doctors suggested could be causing the hair loss.
User experienced severe allergic reactions and liver issues after a hair transplant, likely due to antibiotics and medications. Despite trying Minoxidil, the user faced further complications and is now seeking medical advice for potential future transplants.
The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.